What is Tempest Therapeutics?
Headquartered in Brisbane, California, and publicly traded on Nasdaq under the ticker TPST, Tempest Therapeutics is at the forefront of medical innovation. The company specializes in the development of advanced therapeutic candidates, most notably its dual-target CD19/BCMA CAR-T therapy, TPST-4003. By leveraging a proprietary mRNA lipid nanoparticle delivery system, Tempest is effectively addressing significant unmet medical needs in relapsed/refractory multiple myeloma, myasthenia gravis, and multiple sclerosis. The company's strategic focus on in vivo applications represents a paradigm shift in how complex diseases are treated, moving away from traditional ex vivo methods toward more scalable, patient-centric solutions.
How much funding has Tempest Therapeutics raised?
Tempest Therapeutics has raised a total of $96.1M across 5 funding rounds:
Series A
$5M
Series B
$70M
Share Placement
$15M
Stock/Share Issuance
$2M
Stock/Share Issuance
$4.1M
Series A (2011): $5M, investors not publicly disclosed
Series B (2018): $70M led by Foresite Capital, F-Prime Capital Partners, Versant Ventures, Quan Capital, Inception Sciences, Eight Roads Ventures, and Lilly Asia Ventures
Share Placement (2022): $15M, investors not publicly disclosed
Stock/Share Issuance (2026): $2M featuring Factor Bioscience
Stock/Share Issuance (2026): $4.1M, investors not publicly disclosed
Key Investors in Tempest Therapeutics
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world, leveraging extensive pharmaceutical and scientific expertise.
What's next for Tempest Therapeutics?
Following this major strategic investment, Tempest Therapeutics is well-positioned to scale its clinical pipeline and refine its mRNA delivery technology. The company's roadmap involves deepening its partnership with Novatim Immune Therapeutics to expedite the regulatory pathway for its lead assets. As the firm transitions into more advanced clinical phases, the focus will likely shift toward optimizing manufacturing processes and expanding the therapeutic utility of its platform. By maintaining a disciplined approach to research and development, Tempest aims to translate its scientific breakthroughs into commercial success, ultimately providing transformative treatment options for patients suffering from chronic autoimmune conditions and aggressive malignancies.
See full Tempest Therapeutics company page
